DexCom Additional Paid In Capital from 2010 to 2025
| DXCM Stock | USD 87.62 1.19 1.38% |
Additional Paid In Capital | First Reported 2011-06-30 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 253.8 M |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.7 B or Operating Income of 721.7 M, as well as many indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 21.88. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Additional Paid In Capital |
Latest DexCom's Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of DexCom Inc over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on DexCom Inc Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x DexCom Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of DexCom Inc shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. DexCom's Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
DexCom Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 701,062,359 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 79.52 | |
| Mean Deviation | 516,171,770 | |
| Median | 1,093,700,000 | |
| Standard Deviation | 557,477,014 | |
| Sample Variance | 310780.6T | |
| Range | 1.3B | |
| R-Value | 0.89 | |
| Mean Square Error | 69145.9T | |
| R-Squared | 0.79 | |
| Slope | 104,229,200 | |
| Total Sum of Squares | 4661709.3T |
DexCom Additional Paid In Capital History
About DexCom Financial Statements
DexCom investors utilize fundamental indicators, such as Additional Paid In Capital, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Additional Paid In Capital | 1.3 B | 1.3 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of DexCom Correlation against competitors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share | Quarterly Revenue Growth 0.02 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.